Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect.
NPJ Vaccines
; 6(1): 130, 2021 Oct 29.
Article
em En
| MEDLINE
| ID: mdl-34716336
ABSTRACT
Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical manifestations, but the bacteria share up to 80-90% genome sequence identity. The recombinant meningococcal serogroup B (MenB) vaccine 4CMenB consists of four antigenic components that can be present in non-B meningococcal and gonococcal strains. This comprehensive review summarizes scientific evidence on the genotypic and phenotypic similarities between vaccine antigens and their homologs expressed by non-B meningococcal and gonococcal strains. It also includes immune responses of 4CMenB-vaccinated individuals and effectiveness and impact of 4CMenB against these strains. Varying degrees of strain coverage were estimated depending on the non-B meningococcal serogroup and antigenic repertoire. 4CMenB elicits immune responses against non-B meningococcal serogroups and N. gonorrhoeae. Real-world evidence showed risk reductions of 69% for meningococcal serogroup W clonal complex 11 disease and 40% for gonorrhea after 4CMenB immunization. In conclusion, functional antibody activity and real-world evidence indicate that 4CMenB has the potential to provide some protection beyond MenB disease.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
NPJ Vaccines
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Estados Unidos